MedTrace Logo

Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer

NCT06929468 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2025-04-16

No results posted yet for this study

Summary

The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck cancer. Researchers will compare patients who are receiving cisplatin chemoradiotherapy to patients who are only receiving radiotherapy. Patients will undergo standardized testing for hearing loss, tinnitus and vestibular dysfunction at baseline, during and after treatment. Optional genetic analyses will aim to identify genes known to predispose to cisplatin-induced ototoxicity.

Conditions

  • Ototoxic Hearing Loss
  • Ototoxicity, Drug-Induced
  • Cisplatin-induced Hearing Loss
  • Cisplatin Ototoxicity
  • Head and Neck Cancer
  • Dizzyness
  • Inner Ear Hearing Loss
  • Vestibular Disease
  • Squamous Cell Carcinoma of the Head and Neck
  • Deafness
  • Hearing Loss

Sponsors & Collaborators

  • Klinikum Nürnberg

    collaborator OTHER

  • Simon Jäger

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06929468 on ClinicalTrials.gov